Elanco Animal Health (NYSE:ELAN) – Investment analysts at William Blair issued their FY2023 EPS estimates for Elanco Animal Health in a research report issued to clients and investors on Wednesday, November 6th. William Blair analyst J. Kreger forecasts that the company will earn $1.68 per share for the year.
A number of other research analysts have also recently commented on the company. Goldman Sachs Group began coverage on Elanco Animal Health in a report on Monday, September 9th. They issued a “positive” rating on the stock. They noted that the move was a valuation call. ValuEngine upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Morgan Stanley upgraded Elanco Animal Health from an “equal” rating to a “weight” rating and decreased their price target for the stock from $34.00 to $32.00 in a research note on Thursday. Barclays initiated coverage on Elanco Animal Health in a research note on Monday, September 23rd. They set an “overweight” rating and a $36.00 price target on the stock. Finally, Zacks Investment Research cut Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $33.41.
Shares of Elanco Animal Health stock traded down $0.60 on Monday, hitting $26.63. The company’s stock had a trading volume of 63,909 shares, compared to its average volume of 5,298,131. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.71 and a current ratio of 3.07. Elanco Animal Health has a 1 year low of $25.51 and a 1 year high of $35.46. The firm has a fifty day moving average price of $26.87 and a 200-day moving average price of $30.28. The company has a market capitalization of $10.03 billion, a price-to-earnings ratio of 22.60 and a beta of 0.69.
Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.04. Elanco Animal Health had a return on equity of 7.83% and a net margin of 4.69%. The firm had revenue of $771.30 million during the quarter, compared to analyst estimates of $765.85 million. During the same quarter in the previous year, the business earned $0.29 EPS. Elanco Animal Health’s revenue for the quarter was up 1.3% compared to the same quarter last year.
In other Elanco Animal Health news, major shareholder Dawei Li bought 1,384,717 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $1.05 per share, with a total value of $1,453,952.85. Also, CEO Jeffrey N. Simmons bought 75,750 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was acquired at an average cost of $26.55 per share, for a total transaction of $2,011,162.50. Following the acquisition, the chief executive officer now directly owns 470,006 shares of the company’s stock, valued at $12,478,659.30. The disclosure for this purchase can be found here. Insiders have bought 1,497,497 shares of company stock worth $4,457,115 in the last ninety days. Corporate insiders own 0.04% of the company’s stock.
A number of large investors have recently bought and sold shares of ELAN. First Allied Advisory Services Inc. raised its stake in Elanco Animal Health by 11.3% during the third quarter. First Allied Advisory Services Inc. now owns 8,908 shares of the company’s stock worth $239,000 after acquiring an additional 905 shares in the last quarter. Perennial Advisors LLC raised its stake in Elanco Animal Health by 32.7% during the third quarter. Perennial Advisors LLC now owns 49,296 shares of the company’s stock worth $1,311,000 after acquiring an additional 12,145 shares in the last quarter. Putnam FL Investment Management Co. acquired a new position in Elanco Animal Health during the third quarter worth about $389,000. BBVA USA Bancshares Inc. raised its stake in Elanco Animal Health by 11.3% during the third quarter. BBVA USA Bancshares Inc. now owns 13,708 shares of the company’s stock worth $364,000 after acquiring an additional 1,387 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. raised its stake in Elanco Animal Health by 15.5% during the third quarter. Vestmark Advisory Solutions Inc. now owns 25,108 shares of the company’s stock worth $668,000 after acquiring an additional 3,377 shares in the last quarter.
Elanco Animal Health Company Profile
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.